Ocular Therapeutix, Inc. - Common Stock (OCUL)

EQNX::TICKER_START (NASDAQOKYO),NYSE:NVSNYSENVS)(NASDAQ:ALDXNASDAQALDX,(NASDAQ:OCULNASDAQ),(NASDAQ:EYPTEYPT) EQNX::TICKER_END

Ocular Therapeutix, Inc. (NASDAQOCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will participate at the following conferences:

Ocular Therapeutix, Inc. (NASDAQOCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today reported financial results for the quarter ended September 30, 2022, and provided updates on its ophthalmology pipeline.

Ocular Therapeutix, Inc. (NASDAQOCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will report third quarter ended September 30, 2022 financial results after the close on Monday, November 7, 2022. Following distribution of the earnings release via wire services, the Ocular Therapeutix management team will host a live conference call and webcast at 4:30 p.m. Eastern Time to review the Company’s financial results and provide a general business update.

Ocular Therapeutix, Inc. (NASDAQOCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced interim 7-month data from its U.S. Phase 1 clinical trial evaluating OTX-TKI, the Company’s axitinib intravitreal hydrogel implant being developed for the treatment of wet age-related macular degeneration (wet AMD) and other retinal diseases. The data will be presented in more detail at the upcoming American Academy of Ophthalmology (AAO) 2022 Annual Meeting Subspecialty Day being held in Chicago by Dilsher Dhoot, MD on Friday, September 30th at 3:29 CT and can be accessed approximately two hours after the presentation’s conclusion for 90 days by visiting the investors section of the Company’s website at investors.ocutx.com.

Ocular Therapeutix, Inc. (NASDAQOCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced multiple presentations at the American Academy of Ophthalmology (AAO) 2022 Annual Meeting being held September 30 - October 3, 2022 at McCormick Place Convention Center in Chicago, IL.

Ocular Therapeutix, Inc. (NASDAQOCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will present at the H.C. Wainwright 24th Annual Global Investment Conference on Wednesday, September 14, 2022 at 11:00 AM ET at the Lotte New York Palace Hotel in New York, NY.

Ocular Therapeutix, Inc. (NASDAQOCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will present at the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference on Wednesday, August 17, 2022:

Ocular Therapeutix, Inc. (NASDAQOCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today reported financial results for the quarter ended June 30, 2022, and provided updates on its ophthalmology pipeline.

Ocular Therapeutix, Inc. (NASDAQOCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will report second quarter ended June 30, 2022 financial results after the close on Monday, August 8, 2022. Following distribution of the earnings release via wire services, the Ocular Therapeutix management team will host a live conference call and webcast at 4:30 p.m. Eastern Time to review the Company’s financial results and provide a general business update.

Ocular Therapeutix, Inc. (NASDAQOCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, announced senior leadership changes to strengthen the Company’s alignment around the development of its late-stage ophthalmology product portfolio. The realignment was affected to enhance Ocular’s ability to execute its strategy of building a comprehensive portfolio of assets to treat a broad range of ocular surface and back-of-the-eye retina diseases.

Ocular Therapeutix, Inc. (Nasdaq: OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will present in a fireside chat at the Jefferies Healthcare Conference on Wednesday, June 8, 2022 at 8:00 AM ET at the Marriott Marquis in New York, NY.

Ocular Therapeutix, Inc. (NASDAQOCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today reported financial results for the quarter ended March 31, 2022, and provided updates on its ophthalmology pipeline.

Ocular Therapeutix, Inc. (NASDAQOCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, announced two scientific presentations at the American Society of Gene & Cell Therapy (ASGCT) 25th Annual Meeting being held May 16-19, 2022 in Washington, D.C. and virtually.

Ocular Therapeutix™, Inc. (NASDAQOCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will report first quarter ended March 31, 2022 financial results on Monday, May 9, 2022. Following distribution of the earnings release via wire services, the Ocular Therapeutix management team will host a live conference call and webcast at 4:30 p.m. Eastern Time to review the Company’s financial results and provide a general business update.

Ocular Therapeutix, Inc. (NASDAQOCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, announced multiple scientific presentations at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting being held May 1-4 in Denver, Colorado and May 11-12 virtually.

Ocular Therapeutix, Inc. (NASDAQOCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, announced multiple scientific presentations at the 2022 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting being held April 22-26, 2022 in Washington, D.C.

Ocular Therapeutix™, Inc. (Nasdaq: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will report fourth quarter and year-end financial results on Monday, February 28, 2022, after the market close. Following distribution of the earnings release via wire services, the Ocular Therapeutix management team will host a live conference call and webcast at 4:30 p.m. Eastern Time to review the Company’s financial results and provide a general business update.

Ocular Therapeutix, Inc. (NASDAQOCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced its intention to present data at two medical meetings. Data from the Phase 1 Australian-based clinical trial of OTX-TKI, an axitinib intravitreal implant for the treatment of patients with wet age-related macular degeneration (wet AMD) and other retinal diseases, will be presented at the Angiogenesis, Exudation, and Degeneration 2022 Meeting being held on February 11-12th. The Company will also present data from the Phase 1 US-based clinical trial of OTX-TIC, an intracameral implant of travoprost for the treatment of glaucoma and ocular hypertension at the Glaucoma 360 Meeting on February 11th.

Ocular Therapeutix, Inc. (NASDAQOCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that AffaMed Therapeutics dosed its first patient in a real-world setting study being conducted in China evaluating the safety and efficacy of DEXTENZA® (0.4 mg dexamethasone ophthalmic insert) for the treatment of ocular inflammation and pain post-cataract surgery. In 2020, Ocular entered into a licensing agreement with AffaMed Therapeutics for the development and commercialization of DEXTENZA® in Greater China, South Korea, and the ASEAN markets. DEXTENZA® is currently approved in the U.S. for the treatment of ocular inflammation and pain following ophthalmic surgery and for the treatment of ocular itching associated with allergic conjunctivitis.

Ocular Therapeutix, Inc. (Nasdaq: OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will present at the H.C. Wainwright BioConnect 2022 Virtual Conference being held January 10-13, 2022.

Ocular Therapeutix, Inc. (NASDAQOCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced positive topline results from its Phase 2 clinical trial of OTX-DED (dexamethasone intracanalicular ophthalmic insert) for the short-term treatment of dry eye disease.

Ocular Therapeutix, Inc. (Nasdaq: OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will participate at the following conferences:

Ocular Therapeutix, Inc. (NASDAQOCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that the U.S. Court of Appeals for the Federal Circuit in Washington, D.C., invalidated a patent held by Mati Therapeutics, Inc. (Mati) relating to a drug delivery system containing dexamethasone. This decision affirms the judgment made in June 2020 by the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office after an inter partes review that determined Ocular Therapeutix had proven that all 23 claims of U.S. Patent 9,849,082 B2 (the ‘082 patent), owned by Mati are invalid due to “obviousness”. Mati had previously claimed that Ocular Therapeutix’s first commercial drug product, DEXTENZA®, and its hydrogel platform, had infringed the ‘082 patent.

Ocular Therapeutix, Inc. (NASDAQOCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today reported financial results for the third quarter of 2021, and provided updates on its ophthalmology pipeline.